Curaleaf HoldingsCURLF +3.19%67 Earnings Yield (Joel Greenblatt) % is 0.48% as of Mar. 2026. GuruFocus rates CURLF with a GF Score™ of 67/100 and a GF Value™ of $7.98 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,013 Drug Manufacturers companies, Curaleaf Holdings ranks worse than 65.75% on this metric.
Curaleaf Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $2,487 Mil.
Curaleaf Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $12 Mil. Curaleaf Holdings's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 0.48%.
The historical rank and industry rank for Curaleaf Holdings's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CURLF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -39.57 Med: -0.53 Max: 64.37
Current: 0.36
During the past 12 years, the highest Earnings Yield (Joel Greenblatt) of Curaleaf Holdings was 64.37%. The lowest was -39.57%. And the median was -0.53%.
CURLF's Earnings Yield (Joel Greenblatt) % is ranked worse than 65.75% of 1013
companies
in the Drug Manufacturers industry
Industry Median: 3.23
vs CURLF: 0.36
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Curaleaf Holdings's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was -3.24%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Curaleaf Holdings Earnings Yield (Joel Greenblatt) % Related Terms
Curaleaf Holdings Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Curaleaf Holdings's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CURLF vs ZTS, UTHR: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Curaleaf Holdingss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Curaleaf Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $12 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 0.48% mean?
Curaleaf Holdings (CURLF) has a Earnings Yield (Joel Greenblatt) % of 0.48% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Curaleaf Holdings and its competitors. According to the industry distribution chart, Curaleaf Holdings ranks #666 out of 1013 companies in the Drug Manufacturers industry, placing it in the top 65.7%.
Is Curaleaf Holdings' Earnings Yield (Joel Greenblatt) % too high?
Curaleaf Holdings' current Earnings Yield (Joel Greenblatt) % is 0.48%. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.23. Curaleaf Holdings' value of 0.48% is 85.1% below this industry median. Based on the distribution chart, Curaleaf Holdings ranks #666 out of 1013 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Curaleaf Holdings has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #666 out of 1013 companies for Earnings Yield (Joel Greenblatt) %. This places Curaleaf Holdings in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.23. Curaleaf Holdings' value of 0.48% is 85.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.23, based on 1,013 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current Earnings Yield (Joel Greenblatt) % of 0.48% is 85.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current Earnings Yield (Joel Greenblatt) % is 0.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (CURLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.98, compared to a current price of $9.70 — trading 21.6% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 0.48% and 85.1% below the Drug Manufacturers industry median of 3.23. Curaleaf Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Curaleaf Holdings (CURLF), the current Earnings Yield (Joel Greenblatt) % is 0.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (CURLF) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of $9.70 is trading 21.6% above its estimated GF Value™ of $7.98.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for CURLF:
Earnings Yield (Joel Greenblatt) %: 0.48%
GF Value™: $7.98 vs. price of $9.70 (21.6% above fair value)
Industry Position: 85.1% below the Drug Manufacturers median (#666 of 1013)
No single metric tells the full story. See the CURLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
67GF Score
Get the complete analysis for CURLF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURLF has been successfully added to your 
